
ALT Graphical data showing changes in liver fat content as measured by MRI-PDFF. The top graph (A) indicates "Percent Change in Liver Fat by MRI-PDFF over Time." It features a pooled placebo group (gray line) and four treatment groups showing different doses of CIDEBsiRNA (15 mg, 30 mg, 60 mg, and 600 mg) (blue lines). The bottom graph (B) illustrates "Absolute Values of Liver Fat by MRI-PDFF over Time." TSimilar to graph (A), the treatment groups are plotted against the pooled placebo with the same dosages over a 36-week period. A table at the bottom displays the number of participants for each group.

ALT Graphical data showing changes in liver fat content as measured by MRI-PDFF. The top graph (A) indicates "Percent Change in Liver Fat by MRI-PDFF over Time." It features a pooled placebo group (gray line) and four treatment groups showing different doses of CIDEBsiRNA (15 mg, 30 mg, 60 mg, and 600 mg) (blue lines). The bottom graph (B) illustrates "Absolute Values of Liver Fat by MRI-PDFF over Time." TSimilar to graph (A), the treatment groups are plotted against the pooled placebo with the same dosages over a 36-week period. A table at the bottom displays the number of participants for each group.

















